{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005292","form_type":"8-K","ticker":"DLB","cik":"0001308547","company_name":"Dolby Laboratories, Inc.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.576255+00:00","generated_at":"2026-06-30T00:50:43.653490+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dolby Q3 FY2021 revenue $286.8M (+16% YoY) but GAAP EPS down to $0.52 from $0.66","bullets":["Revenue $286.8M (up 16% YoY from $246.9M); GAAP net income $54.6M ($0.52 eps) vs $67.3M ($0.66) prior year.","Non-GAAP EPS $0.71 vs $0.86 prior year; operating cash flow $172.4M vs $134.3M.","Board increased share repurchase authorization by $350M to ~$387M; dividend $0.22/share payable Aug 19.","Q4 FY2021 guidance: revenue $280M-$310M; GAAP EPS $0.25-$0.40; non-GAAP EPS $0.47-$0.62.","Full year FY2021 guidance: revenue $1.28B-$1.31B; GAAP EPS $2.79-$2.94; non-GAAP EPS $3.57-$3.72."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005292","json":"https://secwatch.observer/filing/0001171843-21-005292.json","markdown":"https://secwatch.observer/filing/0001171843-21-005292.md","text":"https://secwatch.observer/filing/0001171843-21-005292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1308547/000117184321005292/0001171843-21-005292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1308547/000117184321005292/f8k_072821.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:50:43.653490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}